People

Gary R. Schall

Partner

Schall, Gary R.

Gary Schall helps entrepreneurs and emerging companies navigate the many legal issues they face, from formation to equity and note financings through exit events. He also represents venture capital funds in their investments in startups and high-growth companies. His clients are technology-based and span a broad range of industries, including e-commerce, mobile technologies, hardware, software, telecommunications and life sciences.

For more than 15 years, Mr. Schall has represented both venture capital firms and emerging companies advising on a variety of corporate matters, including formation and corporate governance, contract negotiations, employment and equity compensation matters, securities laws compliance and protection of intellectual property. He also counsels his clients through complex transactions, such as convertible debt and preferred stock financings, joint ventures and buy- and sell-side mergers and acquisitions.

Mr. Schall particularly enjoys working with emerging companies—learn more about how he can support your startup on WilmerHaleLaunch.com.

Experience

Prior to joining WilmerHale, Mr. Schall was an of counsel for seven years at a law firm in Boston, Massachusetts. He also held associate positions while at other law firms in Boston and Princeton, New Jersey.

With a background in accounting, Mr. Schall relied on his knowledge of financial modeling to develop business solutions for his clients. He also drew from his background and experiences in order to advise a number of venture capital firms and emerging companies on an array of corporate transactions. 

Recent Highlights

Mr. Schall represents emerging companies in various stages of development and he advises venture capital funds on their investments in early-stage companies.

Representative Financing Transactions

  • the Series Seed Preferred Stock financing of Cloze, Inc. by a venture capital firm;
  • the Series Seed Preferred Stock financing of a private smart video camera company by a venture capital firm and angel investors;
  • the Series Seed Preferred Stock financing of a private data management solutions company by a venture capital firm and angel investors;
  • the Series Seed Preferred Stock financing of Grove Labs Inc. by a venture capital firm;
  • the Series A Preferred Stock financing of Vtesse, Inc. by several strategic investors and venture capital firms;
  • the Series A Preferred Stock financing of Immuta, Inc. by multiple venture capital firms;
  • Spark Capital III L.P. in the Series A Preferred Stock Financing of PrefTV, Inc.;
  • Spark Capital III, L.P. in the Series A Preferred Stock financing of Orchard App Inc. and various investments in other portfolio companies;
  • the Series A-1 Preferred Stock financing of Vgo Communications, Inc. by a venture capital firm;
  • the Series B and Series B Extension Preferred Stock financing of MineralTree, Inc. by a strategic investor and several venture capital funds;
  • the Series B Preferred Stock financing of Fiksu, Inc. by a strategic investor and several venture capital funds;
  • the Series B Preferred Stock financing of Spark Therapeutics by a strategic investor and several venture capital funds;
  • Spark Capital III, L.P. and Matrix Partners IX, L.P. in the Series B Preferred Stock financing of Oculus VR, Inc.;
  • a venture capital firm in a Series B Preferred Stock financing of a private medical device company;
  • the Series C Preferred Stock financing of 1366 Technologies, Inc. by several strategic investors and venture capital firms;
  • the Series D Preferred Stock financing of MC10, Inc. by several strategic investors and venture capital firms; and
  • the Series D Preferred Stock financing of Cool Planet Energy Systems, Inc. by several strategic investors and venture capital firms.

Representative M&A Transactions and Joint Ventures

  • the acquisition of Smarterer Inc. by Pluralsight Inc.;
  • the acquisition of an angel-backed patient reported outcomes solutions provider by a private equity-backed patient experience solutions provider;
  • the acquisition of a venture-backed medical device company by a public medical device company;
  • the joint venture of a venture-backed company and a public grocery company; and
  • the joint venture of Atlas Venture Fund and a public pharmaceutical company.

Professional Activities

Mr. Schall is a member of the American Bar Association and serves as Secretary on the Board of Directors of the Swedish-American Chamber of Commerce New England.

Additionally, Mr. Schall writes on topics related to entrepreneurship and has been featured on The Accelerators blog by The Wall Street Journal, Xconomy and TechCrunch. He is a frequent guest lecturer for various entrepreneurship organizations including the MIT Enterprise Forum of Cambridge, Swedish-American Chamber of Commerce New England and the Harvard i-lab.

Publications & News

View

April 12, 2018

You’ve Signed a Term Sheet for Your First Equity Financing. Congratulations! … Now What?

Gary Schall, in this article published by The Recorder, shares six critical steps founders can take to forge a strong and open relationship with their new business partners.

December 17, 2017

Your Startup Should Not Be an LLC

Partner Gary Schall, in this guest article published by VentureBeat, discusses the complexities of organizing as an LLC and when that path may or may not be right for your startup.

October 19, 2017

WilmerHale Reps Cydan in Raising $34M to Accelerate New Treatments for Rare Genetic Diseases

Cydan, the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare genetic diseases, announced a new round of financing, raising a committed total of $34 million to advance the company's efforts to create new and innovative therapies for patients living with rare genetic diseases.

May 10, 2017

Alumni from iRobot and HubSpot Launch Owl Labs and Announce $6M Series A Funding

WilmerHale client Owl Labs announced a $6M Series A financing led by Matrix Partners.

May 10, 2017

Why You’re Wiser With an Adviser

Gary Schall, in this article published by Xconomy, explains why it is necessary for startup companies to invest in an adviser.

May 8, 2017

WilmerHale Counsels Exonics Therapeutics in $5M Seed Financing

The newly formed biotechnology company focused on developing gene editing technologies to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, announced a commitment of $5 million in seed financing from CureDuchenne Ventures.

April 25, 2017

Cool Planet Closes on Nearly $20M to Fund Commercialization of Engineered Biocarbon Products

WilmerHale counseled agriculture technology company Cool Planet in the closing of a $19.3 million Series A financing to commercialize its Cool Terra and Cool Fauna engineered biocarbon products.

April 3, 2017

WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, and Vtesse Inc., a privately-held rare disease company, today announced that Sucampo has acquired Vtesse for upfront consideration of $200 million.

February 21, 2017

WilmerHale Advises Immuta in $8M Series A Funding

Immuta, the unified data platform for the world's most secure organizations, announced an $8 million Series A round bringing the company's total funding to $9.5 million to date.

January 19, 2017

Want to Ruin Your Relationships? Ask Family and Friends to Fund Your Startup

In this article published by Xconomy, Gary Schall explains why obtaining capital from friends and family can be a lose-lose proposition for entrepreneurs and suggests other avenues to pursue instead.

Practices

Skip Navigation Links.

Education

JD, Vanderbilt University Law School, 2000, Articles Editor, Vanderbilt Journal of Transnational Law, Order of the Coif

MBA, St. John's University, 1991

BS, Finance, Lehigh University, 1987

Bar Admissions

Massachusetts

Skip Navigation Links.